{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T21:20:51Z","timestamp":1793740851693,"version":"4.6.1"},"reference-count":13,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"23","license":[{"start":{"date-parts":[[2020,6,5]],"date-time":"2020-06-05T00:00:00Z","timestamp":1591315200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"The National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81170472"],"award-info":[{"award-number":["81170472"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Tianjin Provincial Key Research and Development Program","award":["18ZXDBSY00140"],"award-info":[{"award-number":["18ZXDBSY00140"]}]},{"name":"Application Bases and Advanced Technology Research Program of Tianjin","award":["14JCYBJC27200, 09JCYBJC112 00"],"award-info":[{"award-number":["14JCYBJC27200, 09JCYBJC112 00"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Rationale:<\/jats:title>\n            <jats:p>It is very difficult to treat patients with aplastic anemia accompanied by chronic kidney disease. The nephrotoxicity of cyclosporine limits its use in these patients. Most of these patients also lack suitable sibling donors. Sirolimus, as a new type of immunosuppressive agent, has good therapeutic effect, lower toxicity, especially lower nephrotoxicity, thus attracting the attention of hematologists.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patient concerns:<\/jats:title>\n            <jats:p>This 55-year-old Chinese male patient suffered from pancytopenia and renal insufficiency and has a poor quality of life.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Diagnosis:<\/jats:title>\n            <jats:p>The patient was diagnosed as severe aplastic anemia with chronic kidney disease-G3a.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Interventions:<\/jats:title>\n            <jats:p>We started the sirolimus therapy with the initial dose of 1\u200amg per day. Based on the good tolerability and clinical effect, we increased the dose of sirolimus to 2\u200amg per day after 2 weeks.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Outcomes:<\/jats:title>\n            <jats:p>By taking sirolimus, the patient's peripheral blood cell count gradually increased, and he achieved blood transfusion independent, and eventually the blood cell count was completely normal.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Lessons:<\/jats:title>\n            <jats:p>We consider that sirolimus is a safe, effective, and well-tolerated oral drug that can be used as a treatment for aplastic anemia patients with chronic kidney disease.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000020669","type":"journal-article","created":{"date-parts":[[2020,6,3]],"date-time":"2020-06-03T20:08:32Z","timestamp":1591214912000},"page":"e20669","source":"Crossref","is-referenced-by-count":7,"title":["Successful sirolimus therapy of an aplastic anemia patient with chronic kidney disease"],"prefix":"10.1097","volume":"99","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9324-7699","authenticated-orcid":false,"given":"Haiyue","family":"Niu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiwei","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yihao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Limin","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zonghong","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaquan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2020,6,5]]},"reference":[{"key":"R1-20230915","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1182\/blood-2006-03-010777","article-title":"Current concepts in the pathophysiology and treatment of aplastic anemia","volume":"108","author":"Young","year":"2006","journal-title":"Blood"},{"key":"R2-20230915","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1182\/blood-2016-08-693481","article-title":"How I treat acquired aplastic anemia","volume":"129","author":"Bacigalupo","year":"2017","journal-title":"Blood"},{"key":"R3-20230915","doi-asserted-by":"crossref","first-page":"4517","DOI":"10.1182\/blood-2001-11-0062","article-title":"Effect of rapamycin on the cyclosporin A resistant CD28-mediated costimulatory pathway","volume":"99","author":"Ghosh","year":"2002","journal-title":"Blood"},{"key":"R4-20230915","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1182\/blood.V45.3.355.355","article-title":"Selection of patients for bone marrow transplantation in severe aplastic anemia","volume":"45","author":"Camitta","year":"1975","journal-title":"Blood"},{"key":"R5-20230915","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1038\/ki.2014.31","article-title":"KDIGO clinical practice guideline for Lipid management in CKD: summary of recommendation statements and clinical approach to the patient","volume":"85","author":"Wanner","year":"2014","journal-title":"Kidney Int"},{"key":"R6-20230915","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s12185-011-0816-9","article-title":"Successful immunosuppressive and iron chelation therapy for a severe aplastic anemia patient undergoing hemodialysis due to chronic renal failure","volume":"93","author":"Hiraga","year":"2011","journal-title":"Int J Hematol"},{"key":"R7-20230915","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/sj.bmt.1703584","article-title":"Successful allogeneic blood stem cell transplantation for aplastic anemia in a patient with renal insufficiency requiring dialysis","volume":"30","author":"Hamaki","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"R8-20230915","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/pbc.22865","article-title":"Relapse of aplastic anemia responsive to sirolimus combined with cyclosporine","volume":"56","author":"He","year":"2011","journal-title":"Pediatr Blood Cancer"},{"key":"R9-20230915","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.3324\/haematol.2017.175497","article-title":"Rapamycin targets several pathophysiological features of immune-mediated bone marrow failure in murine models","volume":"102","author":"Weston","year":"2017","journal-title":"Haematologica"},{"key":"R10-20230915","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.3324\/haematol.2017.163675","article-title":"Rapamycin is highly effective in murine models of immune-mediated bone marrow failure","volume":"102","author":"Feng","year":"2017","journal-title":"Haematologica"},{"key":"R11-20230915","first-page":"196","article-title":"Rapamycin affect the apoptosis of splenic CD4+CD25+ regulatory T cells of mouse severe aplastic anemia model","volume":"39","author":"Lin","year":"2018","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"key":"R12-20230915","doi-asserted-by":"crossref","first-page":"348","DOI":"10.3324\/haematol.13829","article-title":"Treatment of severe aplastic anemia with a combination of horse antithymocyte globulin and cyclosporine, with or without sirolimus:a prospective randomized study","volume":"94","author":"Scheinberg","year":"2009","journal-title":"Haematologica"},{"key":"R13-20230915","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.cell.2017.03.035","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"169","author":"Saxton","year":"2017","journal-title":"Cell"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020669","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,16]],"date-time":"2023-09-16T00:05:10Z","timestamp":1694822710000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000020669"}},"subtitle":["A case report"],"short-title":[],"issued":{"date-parts":[[2020,6,5]]},"references-count":13,"journal-issue":{"issue":"23","published-online":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000020669","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"value":"0025-7974","type":"print"},{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,5]]}}}